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Apolipoprotein E (APOE) is the strongest genetic risk
factor for Alzheimer’s disease (AD). Previous studies
suggest that the effect of apoE on amyloid-b (Ab)
accumulation plays a major role in AD pathogenesis.
Therefore, understanding proteins that control apoE
metabolism may provide new targets for regulating
Ab levels. LDLR, a member of the LDL receptor family,
binds to apoE, yet its potential role in AD patho-
genesis remains unclear. We hypothesized that
LDLR overexpression in the brain would decrease
apoE levels, enhance Ab clearance, and decrease
Ab deposition. To test our hypothesis, we created
several transgenic mice that overexpress LDLR in
the brain and found that apoE levels in these mice
decreased by 50%–90%. Furthermore, LDLR over-
expression dramatically reduced Ab aggregation
and enhanced Ab clearance from the brain extracel-
lular space. Plaque-associated neuroinflammatory
responses were attenuated in LDLR transgenic
mice. These findings suggest that increasing LDLR
levels may represent a novel AD treatment strategy.
INTRODUCTION
Accumulation of the amyloid b peptide (Ab) in the brain is hypoth-
esized to trigger pathogenic cascades that eventually lead to
Alzheimer’s disease (AD) (Hardy, 2006). Therefore, strategies
modulating production, clearance, and aggregation of Ab are
actively being pursued as disease modifying therapies in AD
(Golde, 2006). Ab peptides are generated by the sequential
proteolytic processing of amyloid b precursor protein (APP) by
the b- and g-secretase (Cole and Vassar, 2007; Sisodia and St
George-Hyslop, 2002; Steiner and Haass, 2000). Extensive
genetic research on familial AD (FAD) led to the identification
of mutations in the APP, presenilin 1 (PSEN1), and presenilin 2
(PSEN2) genes and provided strong support for the critical role
of Ab accumulation in AD pathogenesis (Hardy, 2006). Many
research groups have utilized this genetic information to develop632 Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc.transgenic mouse models that recapitulate key pathological
phenotypes of AD. These transgenic mice models have been
useful in understanding the etiology of AD and for testing
potential therapeutic approaches for preventing Ab-dependent
pathologies.
Although mutations in FAD-liked genes are known to cause
rare forms of FAD, the 34 allele of apolipoprotein E (APOE) is
the only firmly established genetic risk factor for more common
forms of AD (Bertram et al., 2007b). ApoE functions as a ligand
in the receptor-mediated endocytosis of lipoprotein particles
(Kim et al., 2009). After apoE binds to low density lipoprotein
(LDL) receptor family members, the ligand-receptor complex is
taken up by clathrin-mediated endocytosis and dissociated in
endosomes. Upon dissociation, the apoE receptor recycles
back to the cell surface, whereas the apoE-containing lipopro-
tein particle is targeted to the lysosome wherein cholesterol
becomes available for cellular needs. Although it is not
completely clear how apoE influences the various pathogenic
processes implicated in AD, several lines of evidence suggest
that the effects of apoE on Ab aggregation and clearance play
a major role in AD pathogenesis (Kim et al., 2009). Previous
studies demonstrated that the absence of apoE leads to
a dramatic decrease in the levels of fibrillar Ab deposits in APP
transgenic mouse models (Bales et al., 1997, 1999; Holtzman
et al., 2000a, 2000b). Furthermore, recent studies strongly
suggest that apoE regulates both extracellular and intracellular
Ab clearance in the brain (Bell et al., 2007; Deane et al., 2008;
DeMattos et al., 2004; Jiang et al., 2008). Therefore, modulating
the function of proteins that control apoE metabolism in the brain
will likely alter the extent of amyloid deposition and ultimately
affect the disease process. In support of this possibility, it was
recently demonstrated that ATP-binding cassette transporter
A1 (ABCA1)-mediated lipidation of apoE modulates amyloid
plaque formation (Hirsch-Reinshagen et al., 2005; Koldamova
et al., 2005; Wahrle et al., 2005, 2008). Consequently, further
insight into how apoE levels can be regulated in the brain may
lead to novel therapeutic avenues for the prevention and
treatment of AD.
ApoE binds to a group of structurally related proteins known
as the low density lipoprotein receptor (LDLR) family. This
family includes LDLR, lipoprotein receptor-related protein 1
(LRP1), lipoprotein receptor with 11 binding repeats (LR11),
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Reduction of Ab Deposition by LDLR OverexpressionFigure 1. Expression of LDLR Transgene in Neurons and Astrocytes
(A) Levels of LDLR protein in the cortex of five different LDLR transgenic lines
were assessed by western blotting. RIPA-soluble cortex lysates from LDLR
transgenic mice and nontransgenic (NTG) mice were probed with anti-LDLR
antibody (Novus).
(B–D) Regional expression patterns of LDLR in B line mice were characterized
by immunostaining with anti-HA antibody to detect HA-tagged LDLR protein.
LDLR was expressed in the cortex (B), dentate gyrus of hippocampus (C), and
Purkinje cell dendrites of cerebellum (D).apolipoprotein receptor 2 (ApoER2), very low density lipoprotein
receptor (VLDLR), and others (Herz and Bock, 2002). They share
several common structural characteristics, such as comple-
ment-type ligand binding repeats, b-propeller domain, and
epidermal growth factor type repeats. The prototype of this
family member is LDLR, which has been extensively studied in
the peripheral tissues for its role in mediating the removal of
cholesterol and cholesteryl ester from the circulation (Brown
and Goldstein, 1986). Genetic defects in LDLR lead to an
impaired lipoprotein clearance from the blood stream and
massive accumulation of cholesterol in the circulation, resulting
in familial hypercholesterolemia. Due to its critical role in the
metabolism of apoB-containing LDL particles, LDLR has been
the focus of much attention in better understating the pathogen-
esis of atherosclerosis and coronary heart disease (Soutar and
Naoumova, 2007). However, the physiological and pathological
function of LDLR in the nervous system remains unclear. In
contrast, the roles of other LDL receptor family members in brain
development and synaptic plasticity are better understood
(Herz, 2009). Furthermore, the modulatory effects of other LDL
receptors on Ab clearance and APP trafficking have been thor-
oughly examined in cellular and animal model systems (Cam
and Bu, 2006). However, the potential role of LDLR in AD patho-
genesis has not been studied extensively. To address this issue,
we created several transgenic mouse lines that overexpress
LDLR in the brain and bred two transgenic lines with the
APPswe/PSEN1DE9 (APP/PS1) transgenic mouse model (Jan-
kowsky et al., 2004). The effects of LDLR overexpression on




of LDLR Transgenic Mice
In order to achieve widespread expression of the LDLR trans-
gene in the brain, we created a construct using the mouse prion
promoter (Borchelt et al., 1996). Six transgenic founders with
LDLR transgene were generated and maintained on a B6/CBA
background. One transgenic line transmitted the LDLR trans-
gene only in males and did not have any detectable transgene
expression in the brain. The five remaining transgenic lines
were screened for LDLR overexpression by western blotting
(Figure 1A). As expected, multiple bands of LDLR proteins
were detected due to extensive posttranslational modifications
(Filipovic, 1989). Two- to 11-fold increases in LDLR protein
levels, relative to nontransgenic (NTG) mice, were detected
in the various founder lines (Figure 1A). The high-expressing
(E–G) Cellular expression profile of the LDLR transgene was examined by
using anti-HA or anti-LDLR antibody. (E) Cortical sections were stained by
double-immunofluorescence labeling for HA (red) and the neuronal marker
NeuN (green). (F) Cell lysates from primary neurons or astrocytes isolated
from LDLR B line transgenic (TG) and NTG mice were analyzed by probing
with either anti-LDLR (Novus) or anti-LDLR (Dr. Bu) antibody, respectively.
(G) Expression of HA-tagged LDLR transgene in primary neurons and astro-
cytes was confirmed by western blotting with anti-HA antibody.
Scale bar, 30 mm. See also Figure S1.Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc. 633
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Reduction of Ab Deposition by LDLR OverexpressionB line and low-expressing E line were selected for further
experiments.
To characterize the regional expression pattern of the LDLR
transgene, brain sections were immunostained using an anti-
hemagglutinin (HA) antibody for the detection of the HA tag
placed in the amino-terminal region of the LDLR sequence. As
expected, the immunostaining pattern with anti-HA antibody
overlapped very well with that of anti-LDLR antibody staining
(Figure S1). Transgene expression, analyzed by anti-HA anti-
body, was detected in cortex, hippocampus, and cerebellum
(Figures 1B–1D). Double immunofluorescence staining with
anti-NeuN, a neuron-specific marker, and anti-HA antibody
demonstrated that most neurons expressed LDLR from the
transgene (Figure 1E). To further examine which cell types
express the transgene, primary neurons or astrocytes were
cultured from LDLR transgenic line B mice. LDLR expression
was analyzed with anti-LDLR antibody or anti-HA antibody
(Figures 1F and 1G). Higher levels of LDLR protein were detected
in both neurons and astrocytes. This expression pattern is con-
sistent with a previous study characterizing the prion promoter
expression vector (Borchelt et al., 1996).
To analyze the functional effect of LDLR overexpression in the
brain, the levels of apoE protein in the brain was analyzed by
apoE enzyme-linked immunosorbent assay (ELISA). Since
LDLR is one of the major apoE endocytic receptors in the brain
(Fryer et al., 2005), we expected that LDLR overexpression
would lead to a reduction in apoE protein levels through
enhanced receptor-mediated endocytosis. There was a signifi-
cant decrease in apoE protein levels in all five lines, ranging
from 50% to 90%, compared to NTG littermates (Figure 2A).
Interestingly, only 2-fold overexpression in LDLR transgenic
line E mice was sufficient to decrease apoE levels by 50% in
the brain. Overexpression of LDLR by more than 5-fold, relative
to NTG mice, led to 80%–90% reduction in apoE levels. We also
analyzed apoE mRNA levels by quantitative RT-PCR. There were
no significant differences in apoE mRNA levels between LDLR
transgenic lines B (>10-fold overexpression) and E (2-fold over-
expression) and their NTG littermates (Figure S2). This suggests
that the higher levels of LDLR in the transgenic mice facilitate
apoE endocytosis from the extracellular space, leading to a
decrease in the amount of extracellular apoE.
The higher levels of LDLR in the transgenic mice may facilitate
apoE endocytosis from the extracellular space, leading to a
decrease in the amount of extracellular apoE.
LDLR Overexpression Decreases ApoE Levels
Even in the Presence of APPswe
and PSEN1DE9 Overexpression
A recent study demonstrated that the APP intracellular domain
may increase apoE protein levels by suppressing the transcrip-
tion of LRP1, another major apoE receptor in the brain (Liu
et al., 2007). Furthermore, altered g-secretase activity by a
PSEN1DE9 mutation has been shown to increase apoE protein
levels by interfering with the endocytosis of LDLR (Tamboli
et al., 2008). Therefore, we evaluated the possibility that overex-
pression of APP and PSEN1DE9 in APP/PS1 transgenic mice
used in our study might attenuate the effect of LDLR overexpres-
sion on apoE levels. To determine whether LDLR overexpression634 Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc.Figure 2. Reduction of Brain ApoE Protein Levels by LDLR Overex-
pression
(A) Cortex from five LDLR transgenic lines and NTG mice were homogenized
with PBS at 3 months of age. Levels of apoE protein in PBS-extracted fraction
were analyzed by apoE ELISA (n = 4 per group).
(B) Hemizygous LDLR B line mice were bred with APP/PS1 transgenic mice.
Levels of PBS-soluble apoE in the cortex (Ctx) and hippocampus (Hip) were
measured from APP/PS1 mice without the LDLR transgene (NTG) and from
APP/PS1/LDLR (TG) mice. To prevent any confounding effect from amyloid
plaque formation and sex difference, mice were analyzed by sex at 2.5 months
of age (n = 5–10 per group).
(C) The progeny of hemizygous LDLR E line bred with APP/PS1 mice were
similarly analyzed for apoE protein levels in the Ctx and Hip. There was
a 55%–60% reduction of apoE levels in LDLR TG mice, compared with NTG
mice (n = 6–8 per group).
Values are mean ± SEM. See also Figures S2 and S3.
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Reduction of Ab Deposition by LDLR Overexpressionstill has a functional effect on apoE protein in the presence of the
APP and PSEN1DE9 transgenes, soluble apoE levels were
analyzed from APP/PS1/LDLR and APP/PS1 transgenic mice
at 2.5 months of age. ApoE levels in cortical and hippocampal
tissues from LDLR line B transgenic mice were significantly
decreased by 90%, compared with NTG mice (Figure 2B). In
the low-expressing line E transgenic mice, there was a 55%–
60% reduction of apoE protein levels in both cortex and hippo-
campus (Figure 2C). The effect size of LDLR overexpression on
apoE protein levels was not different in the absence (Figure 2A)
or presence (Figures 2B and 2C) of APP and PSEN1DE9 overex-
pression. Taken together, these results strongly suggest that
overexpression of APP and PSEN1DE9 does not interfere with
the function of LDLR in our transgenic mice. In addition to the
strong effect of the LDLR transgene on apoE levels, there was
also a sex difference in apoE protein levels. In the absence of
LDLR transgene overexpression, male APP/PS1 mice had
10%–20% less apoE protein in the cortex and hippocampus
compared with female littermates (p = 0.05 and p = 0.06 for
B line Ctx and Hip, respectively, p = 0.02 and p = 0.0008 for
E line Ctx and Hip, respectively) (Figures 2B and 2C). The differ-
ence in apoE protein levels between female and male mice was
unlikely due to differences in endogenous LDLR protein levels,
since LDLR levels were not significantly different between female
and male APP/PS1 mice (Figure S3C).
Previous studies suggest that there may be functional redun-
dancy among LDL receptor family members (Mahley and
Ji, 1999; Wouters et al., 2005). Apolipoprotein J (ApoJ) and ApoE
are the two most abundant apolipoproteins in the brain. ApoJ,
also known as clusterin, has been shown to facilitate fibrillar
amyloid plaque formation (DeMattos et al., 2002). To determine
whether LDLR overexpression had a selective effect on apoE,
we assessed apoJ protein levels by western blot analysis. No
significant difference in the levels of apoJ was found between
LDLR transgenic and NTG mice (Figure S3B). This finding
suggests that even more than 10-fold overexpression of LDLR
does not affect the metabolism of a similar apolipoprotein.
Strong LDLR Overexpression Leads
to Marked Decreases in Amyloid Deposition
Previous studies demonstrated that the lack of apoE led to a
dramatic decrease of amyloid deposition in APP transgenic
mouse models (Bales et al., 1997; Holtzman et al., 2000b). Given
the critical role of apoE in Ab deposition, we hypothesized that
the reduction of extracellular apoE levels by LDLR overexpres-
sion may lead to a decrease in Ab accumulation. To determine
whether LDLR overexpression affects Ab accumulation and
deposition, the high-expressing LDLR transgenic line B mice
were bred with APP/PS1 transgenic mice. The extent of Ab
deposition was analyzed by histochemical and biochemical
methods. Brain sections from 7-month-old APP/PS1 mice
(Figures 3A and 3C) and APP/PS1/LDLR mice (Figures 3B and
3D) were immunostained with biotinylated-3D6 antibody (anti-
Ab 1-5).
In our preliminary studies with APP/PS1 transgenic mice, there
was a significant difference in amyloid plaque load between
female and male mice. Therefore, we planned to analyze the
extent of Ab accumulation by sex in this study. In the absenceFigure 3. Inhibition of Plaque Formation by Strong LDLR Overex-
pression
Brain sections from APP/PS1 mice without LDLR transgene (NTG) (A and C)
and APP/PS1/LDLR B line transgenic mice (TG) (B and D) were immunostained
for Ab using the 3D6 antibody. Scale bar, 300 mm. (E) The extent of plaque
deposition detected by 3D6 antibody was quantified from cortex (Ctx) and
hippocampus (Hip) of APP/PS1 and APP/PS1/LDLR transgenic mice. Female
and male mice were analyzed separately at 7 months of age (n = 6–12 per
group). (F) Brain sections from APP/PS1 and APP/PS1/LDLR TG mice were
stained with X-34 dye that recognizes compact fibrillar plaques. X-34-positive
fibrillar plaque loads in the Ctx and Hip were analyzed by applying an unbiased
stereological method (n = 6–12 per group). Values are mean ± SEM.Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc. 635
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Reduction of Ab Deposition by LDLR Overexpressionof LDLR overexpression, male APP/PS1 mice had a 50%–60%
decrease in amyloid plaque load, compared with female APP/
PS1 littermates (p = 0.0087 and p = 0.0022 for Ctx and Hip,
respectively) (Figure 3E). Quantitative analyses of anti-Ab immu-
nostaining demonstrated that amyloid plaque loads in the cortex
and hippocampus were markedly decreased in APP/PS1/LDLR
transgenic mice compared with APP/PS1 mice (Figure 3E). The
inhibitory effects of LDLR overexpression on Ab accumulation
were observed in both female and male mice.
To further characterize the nature of the deposited plaques,
brain sections were subsequently stained with X-34 dye that
detects fibrillar amyloid deposits. In line with the results from
Ab immunostaining (Figure 3E), there were strong sex differ-
ences in fibrillar amyloid deposition. Female APP/PS1 mice
deposited significantly more fibrillar plaques than did male
APP/PS1 littermates (p = 0.0234 and p = 0.0087 for Ctx and
Hip, respectively) (Figure 3F). Importantly, APP/PS1/LDLR trans-
genic mice exhibited a dramatic 40%–70% decrease in the
X-34-positive fibrillar plaque load in the cortex and hippo-
campus, compared with sex-matched APP/PS1 mice (Fig-
ure 3F). Consistent with the histochemical analyses, biochemical
analyses of Ab levels demonstrated a 50%–75% reduction in
insoluble Ab40 levels (Figure 4A) and a 45%–70% reduction
in insoluble Ab42 levels in the cortex and hippocampus of
Figure 4. Decrease of Ab Accumulation in APP/PS1/LDLR Trans-
genic Mice
Cortical (Ctx) and hippocampal (Hip) tissues from 7-month-old APP/PS1 (NTG)
and APP/PS1/LDLR B line transgenic mice (TG) were sequentially homoge-
nized by using PBS and guanidine buffer. PBS-insoluble Ab40 (A) and Ab42
(B) levels were measured from Ctx and Hip by using a sandwich Ab ELISA
(n = 6–12 per group). Values are mean ± SEM. See also Table S1.636 Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc.APP/PS1/LDLR transgenic mice (Figure 4B). Taken together,
our results from high-expressing LDLR transgenic line B mice
demonstrate that 10-fold LDLR overexpression markedly
decreases Ab accumulation and amyloid deposition.
Two-Fold Overexpression of LDLR Is Sufficient
to Inhibit Amyloid Formation
To determine whether lower levels of LDLR overexpression
would also have a protective effect against Ab accumulation
and deposition, LDLR transgenic line E mice that overexpress
LDLR by 2-fold were bred to APP/PS1 transgenic mice. Levels
of Ab accumulation were analyzed by anti-Ab immunohisto-
chemistry and X-34 staining (Figures 5A and 5B). Amyloid
plaque loads in the cortex and hippocampus were markedly
lower in female APP/PS1/LDLR transgenic mice, compared
with female APP/PS1 mice (Figure 5C). In addition, female
APP/PS1/LDLR mice had a 50%–55% decrease in fibrillar
plaque load in the cortex and hippocampus (Figure 5D). In line
with the histochemical findings, biochemical measurement of
Ab levels demonstrated a 30%–55% reduction in total (soluble
plus insoluble) Ab40 levels and an approximately 35% reduction
in total Ab42 levels in the cortex and hippocampus of APP/PS1/
LDLR transgenic mice (Table S1). In contrast to the effects in
females, there was no significant difference between plaque
load or Ab levels in male APP/PS1 versus APP/PS1/LDLR trans-
genic mice from line E. Collectively, these findings strongly
suggest that even a small increase of LDLR protein levels can
be effective in preventing Ab accumulation in female mice
(Figures 5C and 5D).
Attenuation of Neuroinflammatory Responses
in APP/PS1/LDLR Transgenic Mice
Abnormal activation of microglia and astrocytes is observed in
the brains of AD patients and transgenic mouse models of
amyloidosis (Wyss-Coray, 2006). Previous studies suggest
that fibrillar amyloid plaques may trigger neuroinflammatory
cascades (Meyer-Luehmann et al., 2008). To quantitatively
examine the extent of gliosis, we established a semiautomated
imaging processing method and assessed the activation of
microglia by using CD11b (Figures 6A and 6B) and CD45
(Figures 6D and 6E) as markers. There was an 70% decrease
in the CD11b-positive activated microglial load in APP/PS1/
LDLR line B transgenic mice, compared with APP/PS1 litter-
mates (Figure 6C). Similarly, analysis of CD45-positive microglia
indicated an 80% reduction in area covered by activated
microglia in LDLR transgenic mice (Figure 6F). In addition, brain
sections were stained with anti-glial fibrillary acidic protein
(GFAP) antibody to quantify the extent of astrogliosis (Figures
6G and 6H). Clusters of activated astrocytes were often associ-
ated with amyloid plaques (Figure S4A). APP/PS1/LDLR trans-
genic mice had 45% less GFAP load in cortex compared
with APP/PS1 littermates (Figure 6I). The extent of microgliosis
and astrogliosis were correlated very well with the amount of
compact fibrillar plaques detected with the X-34 dye (Figures
S4B–S4D). These findings demonstrate that the reduction of
fibrillar plaque formation by LDLR overexpression is closely
associated with the decreased activation of microglia and
astrocytes.
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Reduction of Ab Deposition by LDLR OverexpressionLDLR Overexpression Decreases Steady State ISF eAb
Levels in Young Mice and Increases the Elimination
of eAb from the ISF
We reasoned that the marked reduction in Ab deposition in mice
overexpressing LDLR may be the result of altered soluble Ab
metabolism early in life in the extracellular space of the brain
where it is prone to aggregate (Meyer-Luehmann et al., 2003).
To assess this possibility, we performed in vivo microdialysis in
APP/PS1/LDLR line B transgenic mice and APP/PS1 littermates
prior to the onset of amyloid deposition to compare levels of
Figure 5. Two-Fold Overexpression of LDLR Prevents Amyloid
Formation
Hippocampal sections from 7-month-old female APP/PS1 (NTG) (A) and APP/
PS1/LDLR E line transgenic mice (TG) (B) were stained with fibrillar plaque-
specific X-34 dye. Scale bar, 100 mm. (C) The extent of plaque deposition de-
tected by 3D6 antibody was quantified from cortex (Ctx) and hippocampus
(Hip) of APP/PS1 and APP/PS1/LDLR E line transgenic mice. There was no
statistically significant difference between genotypes in male mice. (D) X-34-
positive fibrillar plaque load was analyzed from Ctx and Hip of APP/PS1
and APP/PS1/LDLR transgenic mice (n = 8–13 per group). See also Table
S1. Values are mean ± SEM.soluble Ab in the hippocampal ISF. Soluble ISF Ab exchangeable
across a 38 kDa dialysis membrane (eAb) has previously been
shown to be tightly correlated with the levels of total soluble
Ab present in extracellular pools of the brain (Cirrito et al.,
2003). Theoretically, the actual in vivo steady-state concentra-
tion of an analyte being dialyzed exists at the point at which there
is no flow of the perfusion buffer (Menacherry et al., 1992). To
obtain this value, we varied the flow rate of the perfusion buffer
from 0.3 ml/min to 1.6 ml/min during microdialysis in the hippo-
campus of young APP/PS1/LDLR and APP/PS1 mice (Fig-
ure 7A1). After extrapolating back to the point of zero flow for
each mouse, we found that the mean steady-state concentration
of ISF eAb1-x was significantly lower in APP/PS1/LDLR mice
compared to mice expressing normal levels of LDLR
(Figure 7A2). This difference was not due to differential recovery
of eAb by the probe between groups at any of the flow rates
tested (Figure S5). Since the extent of Ab deposition observed
in Figure 3 was found to depend on the sex of the mice analyzed,
we stratified microdialysis experiments in the same way. We
found that both male and female APP/PS1 mice overexpressing
LDLR had lower steady-state ISF eAb1-x levels compared to their
sex-matched APP/PS1 counterparts (Figure 7A3). Though we
did not observe a similar change in Ab levels as assessed by
conventional biochemical means (Table S2), it is likely that the
Ab sampled during in vivo microdialysis more closely reflects
the extracellular pool than total Abmeasured from tissue homog-
enates.
Given that LDLR overexpression did not appear to alter APP
processing (Figure S3B), and based on our previous finding
that apoE decreased the elimination rate of soluble Ab from
the ISF (DeMattos et al., 2004), we hypothesized that the lower
steady-state concentration of eAb in APP/PS1/LDLR mice is
likely the result of increased elimination from the brain ISF
(Deane et al., 2008; DeMattos et al., 2004). To test this hypoth-
esis, we injected young APP/PS1 and APP/PS1/LDLR mice
intraperitoneally with a potent g-secretase inhibitor in order to
halt Ab production, thus allowing sensitive measurement of
the elimination rate of eAb from the ISF, as previously described
(Figures 7B1 and 7B2) (Cirrito et al., 2003; DeMattos et al.,
2004). The half-life of elimination from the ISF for eAb1-x was
decreased by about 2-fold in APP/PS1/LDLR mice compared
to that measured in APP/PS1 mice (Figure 7B3). The increase
of eAb elimination in LDLR transgenic mice was observed in
both males and females (Figure 7B4). Taken together, these
results demonstrate that increasing expression of LDLR
promotes the elimination of soluble Ab from the ISF, leading to
lower levels of the peptide in the hippocampal extracellular
space. It is likely that the enhanced Ab elimination from the
ISF early in the life of the mice underlies the resulting strong
decrease in Ab accumulation and its consequences such as
inflammation that progress with age.
DISCUSSION
In the current study, we hypothesized that overexpression of
LDLR in the brain would decrease brain apoE protein levels,
subsequently decreasing amyloid deposition. To test this hypoth-
esis, we created several transgenic mouse lines that overexpressNeuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc. 637
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Reduction of Ab Deposition by LDLR OverexpressionFigure 6. Attenuation of Neuroinflammatory Responses in APP/PS1/LDLR Mice
Hippocampal sections from male APP/PS1 (NTG) and APP/PS1/LDLR B line transgenic mice (TG) were immunostained with an antibody against the microglial
marker CD11b (A and B) and CD45 (D and E). Scale bar, 150 mm. The percent area covered by CD11b staining (C) and CD45 staining (F) was quantified from APP/
PS1 and APP/PS1/LDLR B line (n = 8–10 per group). Cortical sections from female APP/PS1 (G) and APP/PS1/LDLR B line transgenic mice (H) were immuno-
stained with anti-GFAP antibody, a marker of astrogliosis. Scale bar, 180 mm. (I) The percent area covered by GFAP staining was quantified (n = 6–8 per group).
Scale bar for higher magnification inserts: 40 mm. All mice were 7 months old. See also Figure S4. Values are mean ± SEM.LDLR in the brain and then bred them with APP/PS1 transgenic
mice. Brain apoE levels in LDLR transgenic mice were decreased
by 50%–90% in a dose-dependent manner. Most importantly,
LDLR overexpression led to dramatic reductions in Ab aggrega-
tion and neuroinflammatory responses. In addition, increasing
expression of LDLR facilitated the elimination of soluble Ab
from the ISF, leading to lower levels of Ab in the hippocampal
extracellular space. This result strongly suggests that LDLR
enhances brain Ab clearance, serving as an important pathway
that modulates Ab metabolism. Overall, the results suggest that
LDLR may be an attractive therapeutic target for AD.
Although numerous putative susceptibility genes for AD have
been reported so far, the strongest genetic risk factor is APOE
genotype; the 34 allele is an AD risk factor and the 32 allele
appears to be protective (Bertram et al., 2007b). Given the
considerable genetic evidence and the immunoreactivity of
apoE in amyloid plaques, the effect of apoE isoforms on Ab
aggregation has been investigated extensively in vitro (Kim
et al., 2009). Later, in vivo studies demonstrated that the lack
of apoE led to a dramatic reduction of fibrillar Ab deposition638 Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc.in APP transgenic mouse models (Bales et al., 1997, 1999;
Holtzman et al., 2000a, 2000b). Furthermore, apoE has been
shown to regulate Ab clearance in the brain (Bell et al., 2007;
Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).
These and other findings strongly suggest that the effects of
apoE on Ab aggregation and clearance play a major role in
AD pathogenesis (Kim et al., 2009). Consequently, modulating
the function or levels of proteins that affect apoE metabolism
in the brain seems to be a logical therapeutic strategy to alter
Ab-dependent pathogenic processes in AD. Results presented
in the current study corroborate the feasibility and efficacy of
apoE targeting therapeutics.
ApoE in the periphery is known to bind to several LDL receptor
family members. Since the lipid composition and lipidation state
of apoE-containing lipoprotein particles are different between
brain and peripheral tissues, it would be important to know which
LDL receptor members can regulate apoE protein levels in the
brain (Kim et al., 2009). Knockout mouse studies have provided
direct evidence for LDLR and LRP1 as major apoE receptors in
the brain (Elder et al., 2007; Fryer et al., 2005; Liu et al., 2007).
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Elimination Half-Life Are Altered in APP/
PS1 Mice Overexpressing LDLR
(A1) An exponential decay regression was used to
fit the concentrations of eAb1-x obtained at each
flow rate for individual mice in both groups. The
equations of the individual regressions were
used to calculate the value at X = 0 for each mouse
in both groups.
(A2) The mean in vivo steady-state concentrations
for ISF eAb1-x (in pg/ml) calculated from the
method in (A1) were 2426 ± 260.5 and 1432 ±
124.8 for APP/PS1 (NTG) and APP/PS1/LDLR
(TG) mice, respectively (n = 12 per group; p =
0.0036, Student’s t test with Welch’s correction).
(A3) The mean in vivo steady-state concentrations
for ISF eAb1-x (in pg/ml) were significantly lower in
APP/PS1/LDLR (TG) mice than in APP/PS1 (NTG)
mice when comparing within the same sex (n = 6
per group; p = 0.049 and 0.040 for male and
female comparisons, respectively).
(B1) After a 6 hr baseline of ISF eAb1-x was
achieved, levels of the peptide rapidly decreased
for both groups studied within several hours of
a 10 mg/kg i.p. injection of the gamma secretase
inhibitor LY411,575.
(B2) The plot of the common logarithm of percent
baseline ISF eAb1-x concentrations versus time
was linear in both groups studied, suggesting net
first-order kinetics. Data shown represent time
points at which Ab levels had not yet plateaued.
The slope from the individual linear regressions
from log(% eAb) versus time for each mouse was
used to calculate the mean half-life (t1/2) of elimina-
tion for eAb from the ISF in (B3).
(B3) The mean eAbt1/2 (in hours) was 1.25 ± 0.0989
(n = 13) and 0.671 ± 0.0833 (n = 12) in NTG and TG
mice, respectively.
(B4) In NTG and TG male mice, the eAbt1/2
(in hours) was 1.13 ± 0.147 (n = 7) and 0.625 ±
0.126 (n = 6), respectively. In NTG and TG female
mice, the eAbt1/2 (in hours) was 1.39 ± 0.112
(n = 6) and 0.717 ± 0.117 (n = 6), respectively.
Differences were significant for comparisons
between males as well as those made for females
of each genotype (p = 0.028 and 0.0018, respec-
tively). See also Figure S5 and Table S2.
Values are mean ± SEM.Fryer et al. also demonstrated that LDLR differentially regulates
the levels of human apoE isoforms in the brain through its binding
specificity. Zerbinatti et al. generated a LRP1 minireceptor trans-
genic mouse model with 3.7-fold increased LRP1 levels in the
brain (Zerbinatti et al., 2004). Although an 25% reduction in
brain apoE levels was observed in LRP1 transgenic mice, there
was an increase in soluble and insoluble Ab in old mice (Zerbi-
natti et al., 2004, 2006). The reason for the LRP1 minireceptor
overexpression causing an increase in Ab levels is not entirely
clear but is likely due to the effects of LRP1 on APP and not
due to its effects on apoE. For example, unlike LDLR, LRP1 is
an APP binding protein that influences APP endocytic traffickingand cellular distribution such that processing to Ab and its extra-
cellular release is enhanced (Pietrzik et al., 2002; Ulery et al.,
2000). This effect of LRP1 on APP and Ab may supersede the
effects of the LRP1 minireceptor on decreasing apoE levels by
25% and its effects on Ab in the brain. In the current study,
only 2-fold overexpression of LDLR protein was sufficient to
decrease brain apoE levels and Ab accumulation by more than
50%. Taken together, these data clearly demonstrate both
LDLR and LRP1 regulate apoE protein levels in the brain.
However, it is unclear whether other LDL receptor family
members, such as LR11, ApoER2, and VLDLR, also efficiently
mediate the endocytosis of apoE in the brain. Given the knownNeuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc. 639
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would be interesting to determine whether the effect of LDLR
overexpression differs in APP transgenic mouse models with
humanized apoE isoforms. In addition, it will be important to
determine the effects of LDLR overexpression on cognitive
abnormalities observed in APP/PS1 mice.
Although the effects of LRP1 on Ab clearance and APP
processing have been extensively studied (Cam and Bu, 2006),
the potential role of LDLR on AD pathogenesis has been unclear.
Several studies reported that a few single-nucleotide polymor-
phisms (SNPs) in LDLR gene are associated with the risk of
developing AD in case-control studies (Cheng et al., 2005;
Gopalraj et al., 2005; Retz et al., 2001). However, others could
not replicate the earlier studies and a meta-analysis of the previ-
ously reported case-control data failed to detect any significant
summary odds ratios (Bertram et al., 2007a; Rodrı´guez et al.,
2006). More recent findings suggest that other SNPs may be
associated with a risk of AD in a sex-specific manner. SNP
rs688 and haplotype GTT were significantly associated with an
increased risk of AD in males and females, respectively (La¨msa¨
et al., 2008; Zou et al., 2008). Unlike other studies, both studies
also demonstrated functional effects of SNPs on LDLR splicing
and Ab42 levels.
In order to investigate the effect of LDLR deficiency on choles-
terol and Ab in the brain, several groups have analyzed LDLR
knockout mice. Although LDLR deficiency significantly
increased murine brain apoE levels by 50%, it did not alter
brain cholesterol levels (Elder et al., 2007; Fryer et al., 2005;
Quan et al., 2003; Taha et al., 2009). Previously, we demon-
strated that there was no significant change in brain Ab levels
both before and after the onset of amyloid deposition in PDAPP
transgenic mice on a LDLR-deficient background (Fryer et al.,
2005). However, there was a trend for an increase in Ab accumu-
lation in PDAPP/LDLR knockout mice. Recently, Buxbaum and
colleagues also reported that LDLR deficiency did not affect
endogenous murine Ab levels in the brain (Elder et al., 2007). In
contrast, lack of LDLR was associated with increased amyloid
deposition in Tg2576 mice (Cao et al., 2006).
Prior to our current study, it was unknown whether increased
levels of LDLR in the brain would affect Ab accumulation
in vivo, and if so, via what mechanism. Given the role of apoE
in Ab clearance and aggregation, we hypothesized that the
reduction of apoE levels by LDLR overexpression would
promote the elimination of soluble Ab from the brain ISF, i.e.,
via transcytosis across the blood-brain barrier into the plasma
or by local cellular uptake and degradation within the brain. We
predicted that increased elimination of soluble Ab through either
of these elimination routes would result in decreased Ab accu-
mulation. Our in vivo microdialysis results suggest that the
mechanism by which LDLR overexpression alters Ab metabo-
lism is to enhance the extracellular clearance of Ab peptide. It
is possible that receptor-mediated clearance of Ab-ApoE
complex or Ab alone from the brain ISF might be enhanced by
LDLR overexpression. Interestingly, other LDL receptor family
members, such as LRP1, LR11, and ApoER2, are known to
directly or indirectly bind to APP and affect its amyloidogenic
processing (Kim et al., 2009). Since levels of carboxyl-terminal
fragments of APP, generated by APP processing, were not640 Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc.different between genotypes, it is unlikely that LDLR overexpres-
sion alters APP processing. Though it is likely that the reduction
of apoE protein levels by LDLR overexpression enhanced Ab
clearance (DeMattos et al., 2004), we cannot exclude the possi-
bility that LDLR may directly affect Ab clearance independent
of apoE.
Transgenic mouse models of amyloidosis have been invalu-
able for investigating AD pathogenic mechanisms and evaluating
the efficacy of novel therapeutic targets. Interestingly, female
APP/PS1 transgenic mice used in the current study had a
more than 2-fold increase in plaque load and insoluble Ab accu-
mulation, compared with male littermates (Figure 3 and 4). Our
finding is consistent with a recent study that used APP/PS1
mice on a different genetic background (Halford and Russell,
2009). A similar sex-specific amyloid deposition phenotype has
been previously reported with other APP transgenic mouse
models (Callahan et al., 2001; Wang et al., 2003). The APP/PS1
transgenic mouse used in our study is one of the most commonly
used Ab amyloidosis models. Effects of genetic and pharmaco-
logical manipulations on Ab accumulation and Ab-related patho-
logical changes have been tested using this model. However,
most previous studies did not analyze the extent of Ab accumu-
lation by sex. It is possible that sex differences were not obvi-
ously recognized in other studies due to the limited sample
size for each sex. Given the dramatic effect of sex on Ab aggre-
gation, the sex of APP/PS1 transgenic mice should be carefully
considered for the proper interpretation of results. Since the
prevalence of AD is higher in women even after adjusting for
age and education levels (Andersen et al., 1999), it is intriguing
that several mouse models of amyloidosis have similar sex-
dependent phenotypes. Several studies suggest that female
hormones may, in part, contribute to sex differences in AD (Car-
roll et al., 2007; Yue et al., 2005). Given the inconsistent findings
among studies, the exact mechanism underlying sex differences
in AD pathogenesis requires further investigation. It is possible
that the elevated apoE levels in the females APP/PS1 mice is
related to why females develop more amyloid deposition (Fig-
ure 2). Interestingly, while the clearance of soluble Ab in APP/
PS1 males trended toward being faster than that for APP/PS1
females (Figure 7B4), we cannot rule out that an Ab clearance-
independent mechanism may account for the sex differences
in plaque load and insoluble Ab accumulation in older mice.
Understanding the factors that regulate sex-dependent pheno-
types may provide additional insight into new therapeutic
targets.
Notably, an increase of LDLR protein levels by only 2-fold
was sufficient to decrease Ab accumulation by 50% in APP/
PS1 female transgenic mice. Our findings suggest that even
a small increase in LDLR levels or function in the brain may be
exploited as a novel approach for developing AD therapeutics.
Due to the critical role of LDLR in the metabolism of apoB-con-
taining LDL particles in the circulation, strategies increasing
the function and amount of LDLR protein in the liver have been
extensively pursued as promising therapies for atherosclerosis
and premature coronary heart disease (Soutar and Naoumova,
2007). Overexpression of LDLR in the liver facilitated LDL elimi-
nation by receptor-mediated endocytosis and prevented diet-
induced hypercholesterolemia (Hofmann et al., 1988; Yokode
Neuron
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brain as a treatment modality for AD has not been previously
investigated. Our study clearly demonstrates the beneficial
effects of LDLR overexpression in the brain on pathogenic Ab
aggregation and subsequent neuroinflammatory responses.
Although other LDL receptor family members bind to multiple
ligands (i.e. LRP1 having more than 20 ligands), there are only
two known ligands, apoB and apoE, for LDLR. Since apoB is
not expressed in the brain, modulating LDLR function in the brain
is likely to target apoE specifically. A couple of recently identified
genes are known to regulate LDLR protein levels by affecting the
trafficking and degradation of LDLR in peripheral tissues (Soutar
and Naoumova, 2007). Since these proteins are also expressed
in the brain, their potential roles in the clearance and accumula-
tion of Ab warrant further investigations. In addition, several
compounds have been identified to increase hepatic LDLR
protein levels by modulating synthesis or degradation of LDLR
and LDLR-regulating proteins. Given our results from transgenic
mice overexpressing LDLR in the brain, the therapeutic potential
of these lead compounds merit additional testing in animal
models of Ab amyloidosis.
EXPERIMENTAL PROCEDURES
Generation of LDLR Transgenic Mice
Murine LDLR was cloned from RNA isolated from mouse brain using the
RNeasy kit (QIAGEN). Random primer RT-PCR was performed using the First
Strand cDNA Synthesis Kit (Roche Applied Sciences). The sequence and
orientation of the insert was verified by complete sequencing. LDLR cDNA
was excised from pcDNA3.1 using XhoI and inserted into the cloning site of
the mouse prion promoter vector (Borchelt et al., 1996), a gift from David
Borchelt (University of Florida). The Mouse Genetics Core Laboratory at Wash-
ington University produced the transgenic mice on a B6/CBA background.
Among six transgenic founders, two lines of LDLR transgenic mice were
crossed with APPswe/PSEN1DE9 (APP/PS1) transgenic mice (line 85, Stock
number 004462, The Jackson Laboratory). APP/PS1 transgenic mice overex-
press a chimeric mouse/human APP695 swedish gene and human PSEN1
with an exon 9 deletion (Jankowsky et al., 2004). All comparisons between
APP/PS1 transgenic mice with or without an LDLR transgene were littermates
on the same genetic background.
Primary Astrocyte Cultures
Cortical primary murine astrocytes were obtained from P2 mouse pups.
Cortices were dissected from the brain and placed in Hanks balanced salt
solution then treated with trypsin/EDTA. Following trypsin digestion, the tissue
was resuspended and triturated in growth media containing DMEM/F12, 20%
fetal bovine serum (FBS), 10 ng/ml epidermal growth factor, 100 units/ml
penicillin/streptomycin, and 1 mM sodium pyruvate. The cell suspension
was then passed through a 100 mm nylon filter and plated into T75 flasks
coated with poly-D-lysine. Once the cells reached confluency, they were
shaken at 100 rpm for 3 hr and the media was aspirated to remove the less
adherent microglial cells. The cells were then passaged into 6-well plates for
experiments.
Primary Neuron Cultures
Cortical primary murine neurons were obtained from E16 embryos. Cortices
were dissected from the brain, cut into small pieces, and placed into HBSS.
The tissue was then treated with trypsin/EDTA for 15 min at 37C. FBS was
then added to the tissue, and it was washed with HBSS (without calcium
and magnesium). Following the wash steps, the tissue was resuspended in
HBSS (-calcium/magnesium) and 500 U/ml of DNase I. The tissue was then
triturated and the cells were resuspended in neurobasal medium with 10%
FBS. Cells were then counted and plated into 6-well plates. Three hoursfollowing the plating, the seeding medium was replaced with neurobasal
medium containing B27 supplement. To remove contaminating glial cells,
a mixture of antimitotics (5-fluoro-20-deoxyuridine, uridine, and cytosine
b-D-arabinofuranoside) was added to the cultures on DIV5. The media was
then changed to neurobasal media with B27 on DIV7.
Quantitative Analyses of Amyloid Deposition
Brain hemispheres were placed in 30% sucrose before freezing and cutting on
a freezing sliding microtome. Serial coronal sections of the brain at 50 mm
intervals were collected from the rostral anterior commisure to caudal hippo-
campus as landmarks. Sections were stained with biotinylated 3D6 (anti-
Ab1-5) antibody or X-34 dye. Stained brain sections were scanned with a
NanoZoomer slide scanner (Hamamatsu Photonics). For quantitative analyses
of 3D6-biotin staining, scanned images were exported with NDP viewer soft-
ware (Hamamatsu Photonics) and converted to 8 bit grayscale using ACDSee
Pro 2 software (ACD Systems). Converted images were thresholded to high-
light plaques and then analyzed by ‘‘Analyze Particles’’ function in the ImageJ
software (National Institutes of Health) (Kim et al., 2007). Identified objects after
thresholding were individually inspected to confirm the object as a plaque or
not. X-34-stained sections were quantified following unbiased stereological
principles (Cavalieri-point counting method) (Holtzman et al., 2000b). Three
brain sections per mouse, each separated by 300 mm, were used for quantifi-
cation. These sections correspond roughly to sections at Bregma –1.7, –2.0,
and –2.3 mm in the mouse brain atlas. The average of three sections was
used to represent a plaque load for each mouse. For analysis of Ab plaque
in the cortex, the cortex immediately dorsal to the hippocampus was
assessed. All analyses were performed in a blinded manner.
Sandwich ELISA for Ab and ApoE
Cortical and hippocampal tissues were sequentially homogenized with PBS
and 5 M guanidine buffer in the presence of 13 protease inhibitor mixture
(Roche). The levels of Ab and ApoE were measured by sandwich ELISA. For
Ab ELISA, HJ2 (anti-Ab35-40) and HJ7.4 (anti-Ab37-42) were used as capture
antibodies and HJ5.1-biotin (anti-Ab13-28) as the detection antibody. WUE4
(Krul et al., 1988) and anti-ApoE antibody (Calbiochem) were used for apoE
ELISA. Pooled C57BL/6J plasma was used as a standard for murine apoE
quantification (Fryer et al., 2005). For in vivo microdialysis experiments, human
Ab1-x from collected fractions was measured using m266 antibody (anti-Ab13-
28) to capture and 3D6-biotinylated antibody (anti-Ab1-5) to detect.
Quantitative Analyses of Neuroinflammatory Response
Brain sections cut with a freezing sliding microtome were immunostained with
anti-CD11b antibody (BD Pharmingen), anti-CD45 antibody (Serotec), and
anti-GFAP antibody (Chemicon). The percent area covered by CD11b and
CD45 staining was analyzed in the hippocampus by using NDP viewer, ACD-
See Pro 2, and NIH Image J softwares, as described above. For GFAP quan-
tification, cortical regions were assessed. The overall area covered by GFAP
staining signals was measured with NDP viewer. Three brain sections per
mouse, each separated by 300 mm, were used for quantification. The average
of three sections was used to estimate the area covered by immunoreactivity
with each antibody. All analyses were performed in a blinded manner.
Western Blot
Cortical tissues, primary neurons, and astrocytes cultures were sonicated in
radioimmunoprecipitation assay (RIPA) buffer (1% NP-40, 1% sodium deoxy-
cholate, 0.1% SDS, 25 mM Tris-HCl, 150 mM NaCl) or 1% Triton X-100 in
the presence of 13 protease inhibitor mixture (Roche). Cortical tissue homog-
enates were centrifuged at 18,000 rcf for 30 min. Primary cells were spun down
at 14,000 rcf for 15 min. Protein concentration in supernatants was determined
using the BCA protein assay kit (Pierce). Equal amounts of protein for each
sample were run on 3%–8% Tris-Acetate or 4%–12% Bis-Tris XT gels (Bio-
Rad) and transferred to PVDF membranes. Blots were probed for LDLR (No-
vus, Abcam, and a gift from Dr. Guojun Bu at Washington University), CT22
(Zymed), HA (Covance) and ApoJ (Covance). Normalized band intensity was
quantified using NIH ImageJ software (Kim et al., 2007).Neuron 64, 632–644, December 10, 2009 ª2009 Elsevier Inc. 641
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In vivo microdialysis in 2.5-month-old APP/PS1 and APP/PS1/LDLR (B-line)
littermates was performed essentially as described (Cirrito et al., 2003; DeMat-
tos et al., 2004). Briefly, microdialysis using the zero flow extrapolated method
was performed with an automated syringe pump (Univentor 864) connected
to a laptop using Univentor 300 software. Zero flow data for each mouse
were fit with an exponential decay regression as described (Menacherry
et al., 1992). For clearance experiments, a stable baseline of ISF eAb levels
was obtained using a constant flow rate of 1.0 ml/min before intraperitoneally
injecting each mouse with 10 mg/kg of the gamma secretase inhibitor
LY411,575 (prepared by dissolving in PBS and propylene glycol). The elimina-
tion of eAb from the ISF followed first-order kinetics; therefore, for each mouse,
the elimination half-life for eAb was calculated using the slope of the linear
regression that included all fractions until levels stopped decreasing.
Statistical Analyses
To determine the statistical significance (*p<0.05, **p<0.01, ***p<0.001),
two-tailed Student’s t test was used, only if the data sets passed the equal
variance test (Levene Median test) and normality test (Kolmogorov-Smirnov
test) (SigmaStat 3.0.). When the data set did not meet the assumptions of
a parametric test, Mann-Whitney Rank Sum Test was performed. The correla-
tion between gliosis and X-34 plaque load was analyzed with Pearson product
moment correlation test (SigmaStat 3.0.). Variability of the measurements was
reported as SEM.
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